Chinese medicine is one of the treasures of Chinese intellectual contributions to mankind.The character⁃istics that distinguish Chinese medicine from conventional Western medicine find its roots in the philosophical(D...Chinese medicine is one of the treasures of Chinese intellectual contributions to mankind.The character⁃istics that distinguish Chinese medicine from conventional Western medicine find its roots in the philosophical(Daoism)concepts of organizing principles to understand the body,health and disease.Key for worldwide acceptance of traditional Chinese medicine(TCM)is the ability to provide scientific evidence in combination with a quality control system based on the bioactive ingredients.Plant quality in relationship to a bioactivity approach is described that is comprised of a variety of novel approaches based on Systems Biology to tackle these issues.Modern scientific technology tools are now avail⁃able to accomplish standardization of TCM products in order to achieve a high level of efficacy and safety,enhancing the introduction into the international markets.The complexity of the many ingredients and the aspect of synergistic bioactivi⁃ties in TCM,limited the analysis for quality control so far only to the major components for each herb and did not provide evidence for a direct relationship with bioactive components.The systems Biology approach,a multi dimensional chemical and pharmacological approach enables linking of the complex metabolic profile of herbs with biological effects and is therefore a key for quality control of TCM material medica,while providing simultaneous scientific evidence for the under⁃lying efficacy and worldwide acceptance of TCM products.Furthermore,a concept of a business gateway comprising several key steps to unlock the business potential of TCM on Western markets will be presented,including the role of European pharmacopeia as well as community mono⁃graphs of the European Medicinal Agency.展开更多
目的评价已发表的非酒精性脂肪性肝病(NAFLD)中医/中西医结合诊疗指南/共识的方法学和报告质量,以期为今后代谢相关脂肪性肝病中医/中西医结合指南/共识的制定提供参考依据。方法计算机检索PubMed、Embase、Web of Science、中国知网、...目的评价已发表的非酒精性脂肪性肝病(NAFLD)中医/中西医结合诊疗指南/共识的方法学和报告质量,以期为今后代谢相关脂肪性肝病中医/中西医结合指南/共识的制定提供参考依据。方法计算机检索PubMed、Embase、Web of Science、中国知网、万方和中国生物医学文献数据库,以及中华中医药学会和中国中西医结合学会的网站(自建库至2024年9月1日)。由两位临床研究人员分别使用指南的研究和评估工具第二版(AGREEⅡ)和国际实践指南报告规范(RIGHT)评价纳入NAFLD中医/中西医结合诊疗指南/共识的方法学质量及报告质量。结果通过文献筛选,最终纳入9篇指南/共识,其中指南4篇,专家共识5篇;采用AGREEⅡ评价9篇指南/共识不同领域得分依次为范围和目的(47.1%)、参与人员(41.0%)、严谨性(21.6%)、清晰性(40.2%)、应用性(19.1%)、独立性(19.6%)。文献推荐级别划分为:B级(修订后推荐)4篇,C级(不推荐)5篇。RIGHT评估显示,“基本信息”与“证据”报告率高,其他领域有待提升。目前,对于NAFLD的中医/中西医结合诊疗指南/共识,尚无国际标准且质量需加强以确保全面性和可信度。结论NAFLD中医/中西医结合诊疗指南/共识的质量仍有提升潜力,应严格遵循AGREEⅡ与RIGHT清单,以确保指南/共识的公正性、科学性与透明度。展开更多
文摘Chinese medicine is one of the treasures of Chinese intellectual contributions to mankind.The character⁃istics that distinguish Chinese medicine from conventional Western medicine find its roots in the philosophical(Daoism)concepts of organizing principles to understand the body,health and disease.Key for worldwide acceptance of traditional Chinese medicine(TCM)is the ability to provide scientific evidence in combination with a quality control system based on the bioactive ingredients.Plant quality in relationship to a bioactivity approach is described that is comprised of a variety of novel approaches based on Systems Biology to tackle these issues.Modern scientific technology tools are now avail⁃able to accomplish standardization of TCM products in order to achieve a high level of efficacy and safety,enhancing the introduction into the international markets.The complexity of the many ingredients and the aspect of synergistic bioactivi⁃ties in TCM,limited the analysis for quality control so far only to the major components for each herb and did not provide evidence for a direct relationship with bioactive components.The systems Biology approach,a multi dimensional chemical and pharmacological approach enables linking of the complex metabolic profile of herbs with biological effects and is therefore a key for quality control of TCM material medica,while providing simultaneous scientific evidence for the under⁃lying efficacy and worldwide acceptance of TCM products.Furthermore,a concept of a business gateway comprising several key steps to unlock the business potential of TCM on Western markets will be presented,including the role of European pharmacopeia as well as community mono⁃graphs of the European Medicinal Agency.
文摘目的评价已发表的非酒精性脂肪性肝病(NAFLD)中医/中西医结合诊疗指南/共识的方法学和报告质量,以期为今后代谢相关脂肪性肝病中医/中西医结合指南/共识的制定提供参考依据。方法计算机检索PubMed、Embase、Web of Science、中国知网、万方和中国生物医学文献数据库,以及中华中医药学会和中国中西医结合学会的网站(自建库至2024年9月1日)。由两位临床研究人员分别使用指南的研究和评估工具第二版(AGREEⅡ)和国际实践指南报告规范(RIGHT)评价纳入NAFLD中医/中西医结合诊疗指南/共识的方法学质量及报告质量。结果通过文献筛选,最终纳入9篇指南/共识,其中指南4篇,专家共识5篇;采用AGREEⅡ评价9篇指南/共识不同领域得分依次为范围和目的(47.1%)、参与人员(41.0%)、严谨性(21.6%)、清晰性(40.2%)、应用性(19.1%)、独立性(19.6%)。文献推荐级别划分为:B级(修订后推荐)4篇,C级(不推荐)5篇。RIGHT评估显示,“基本信息”与“证据”报告率高,其他领域有待提升。目前,对于NAFLD的中医/中西医结合诊疗指南/共识,尚无国际标准且质量需加强以确保全面性和可信度。结论NAFLD中医/中西医结合诊疗指南/共识的质量仍有提升潜力,应严格遵循AGREEⅡ与RIGHT清单,以确保指南/共识的公正性、科学性与透明度。
